focus -WSS

focus

author：entertainment 2025-10-01 00:52:43 - browse：9625

Sarepta - Cambridge -AP — Kristoffer Tripplaar/Sipa via AP

The Food and Drug Administration granted conditional approval Thursday to the first gene therapy for Duchenne muscular dystrophy. Regulators restricted the treatment to younger patients, with additional data required to broaden its use.

The gene therapy, called Elevydis, is made by Sarepta Therapeutics. The company will charge $3.2 million for the treatment, making it the U.S.’s second most expensive drug, behind a recently approved gene therapy for hemophilia. CEO Doug Ingram said on a conference call the price was below what a recently published company-funded analysis found would be cost-effective.

“The approval of Elevidys is a watershed moment for the treatment of Duchenne. Elevydis is the first and only gene therapy approved for Duchenne, and this approval brings us closer to our goal of bringing forward a treatment that provides the potential to alter the trajectory of this degenerative disease,” Ingram said.

Unlock this article by subscribing to STAT+ and enjoy your first 30 days free!

GET STARTED Log In

Previous article： Heart attack and stroke risk calculators need revising
Next article： How a key Senate committee is planning to regulate PBMs

hotspot

focus

WSS

Severe heat forecast: Where scorching temperatures will persist over the next week

Inside the culture of fear in the White House science office of Eric Lander

Feng Zhang, Grail founder join forces on new gene editing startup

The response to Covid

Clinic falsely told dozens they had Alzheimer's, suits say

Transgender women dream of pregnancy via uterus transplants

focus

focus

Wikipedia

Continuity nursing helped my family in our darkest PICU moments

Chronically ill young patients struggle to find fertility info

Dobbs anniversary: the lost opportunity of abortion as health care

Doctors have an ethical obligation to be advocates

Dobbs anniversary: the lost opportunity of abortion as health care

White House finalizes ITC's import ban of latest Apple Watches

Sports medicine is finally prioritizing gender equality

Drone hits Crimean ammunition depot as strikes kill, wound civilians and journalists in Ukraine

Jerome Adams on the need for new antivirals for Covid

Antibiotic resistance and the global rise in human conflict

focus

How to protect coverage of PrEP

Burning questions about Delta and the next phase of the Covid pandemic

Burning questions about Delta and the next phase of the Covid pandemic

A single drug, study failures leave Anavex with nothing but cash

Goldman Sachs launches $650M fund for life science investments

4 missing after record

focus

hotspot

focus

explore